Evolution of Tc-99m in diagnostic radiopharmaceuticals

Seminars in Nuclear Medicine

Volumn 31, Issue 4, 2001, Pages 260-277

  Banerjee, Sharmila ^a   Ambikalmajan Pillai, Maroor Raghavan ^a   Ramamoorthy, Natesan ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHELATE; HYDRAZINONICOTINAMIDE; MOLYBDENUM 99; PEPTIDE; PHOSPHINE DERIVATIVE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RECEPTOR; STEROID; TECHNETIUM 99M; UNCLASSIFIED DRUG;

BONE; BRAIN; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG HALF LIFE; ENERGY; GAMMA RADIATION; HEART; HISTORY OF MEDICINE; HUMAN; HYPOXIA; INFECTION; INFLAMMATION; KIDNEY FUNCTION; LIGHT; OXIDATION; RADIATION EXPOSURE; RADIOCHEMISTRY; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ACTIVITY RELATION; TUMOR;

EID: 0034753128     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2001.26205     Document Type: Article

References (244)

1. Radioactive isotopes of element 43
2. Some chemical properties of element 43
3. Some fission products of uranium
4. The making of missing chemical elements
5. Nuclear isomerism of element 43
6. 99mTc generator technology
7. Introduction: Technetium-99m: An historical perspective
8. Technetium-99m generators: The available options
9. A survey of the production at Brookhaven National Lab of the isotopes for medical research
10. Optimization of scanning method using Tc-99m
11. Properties, uses, radiochemical purity and calibration of Tc-99m
12. Technetium-99m labeled compounds
13. Technetium radiopharmaceuticals-fundamentals, synthesis, structure, and development
14. The development of new radiopharmaceuticals
15. Technetium chemistry and technetium radiopharmaceuticals
16. Physicochemical concepts in the preparation of technetium radiopharmaceuticals
17. Development of new radiopharmaceuticals based on N-substitution of iminodiacetic acid
18. 99mTc-mebrofenin. An improved chole-scintigraphic agent
19. A new complex of Tc-99m for imaging
20. New developments in radiopharmaceuticals for imaging. A review
21. 99mTc-EHDP: A potential radiopharmaceutical for skeletal imaging
22. Technetium-99m methylene diphosphonate-A superior agent for skeletal imaging: Comparison with other technetium complexes
23. 99mTc-skeletal imaging agents
24. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid
25. Crystal structures of coordination compounds
26. Analysis of structural data of technetium compounds
27. 99mTc
28. Structural survey of technetium complexes
29. HPLC analysis of Tc-99m iminodiacetate hepatobiliary agents and a question of multiple peaks: Concise communications
30. 99Tc-DIARS and DMPE complexes containing pentadecanoic acid
31. Studies on some aspects of the instability of Tc-hexamethyl propylene amine-oxime (Tc-HMPAO)
32. 99mTc in aqueous solutions by ligand exchange
33. 99mTc
34. 99mTc-Sestamibi
35. 99mTc-GHA and its evaluation for renal fnnction studies
36. Need for new radiopharmaceuticals
37. Radiopharmaceuticals: State of the art
38. 99mTc-propyleneamine oxime (Tc-99m-PnAO): A potential brain radiopharmaceutical
39. Development of a Tc-99m-labelled radiopharmaceutical for cerebral blood flow imaging
40. Technetium-99m d,l-HM-PAO: A new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion
41. Biological evaluation of the Tc-99m complexes of the d and l isomer of HMPAO
42. Brain radiopharmaceutical
43. 99mTc-D,L-HM-PAO) using gentisic acid
44. Sensitivity of technetium-99m-d,l-HMPAO to radiolysis in aqueous solutions
45. 99mTc-D,L-HM-PAO by methylene blue
46. Brain retention of Tc-99m-ECD is related to in vivo metabolism
47. Radiochemical studies of tetradentate amine-phenols
48. Technetium complexes of tetradentate chiral amine-phenol ligands
49. Technetium-99m complexes of tetradentate amine-phenol ligands: Minor differences in the ligand structure give Tc complexes with significantly different biolocalization
50. Pentadentate chiral aminephenol ligands
51. Technetium complexes of pentadentate amine-phenol ligands
52. 99mTc
53. 99mTc
54. Comparison of Tc-99m aminoalkyl diaminodithiol (DADT) analogs as potential brain blood flow imaging agents
55. Comparative evaluation of Tc-99m labeled aminothiols as possible brain perfusion imaging agents
56. Synthesis and biodistribution of neutral lipid soluble Tc-99m complexes which cross the blood-brain barrier
57. Stereoisomers of neutral oxotechnetium (V) and oxorhenium (V) complexes
58. Comparison of Tc-99m aminoethyl diamidodithiol analogues for brain, blood-flow imaging
59. Pulmonary accumulation of Tc-99m diaminodithiol (DADT) complexes
60. 99mTc-MRP20. A potential brain perfusion agent: In vivo distribution and SPECT studies in non primate animals
61. Quantitative structure distribution relationships (QSDRs) of BATOs
62. Technetium compounds for imaging myocardial and cerebral perfusion
63. A neutral lipophilic technetium-99m complex for regional cerebral blood flow imaging
64. 2 chelate
65. Heart imaging with cationic complexes of technetium
66. Progress in the evaluation and development of Tc-99m radiopharmaceuticals
67. Cationic Tc-99m complexes as potential myocardial imaging agents
68. 99mTc-DMPE in man
69. Biological studies of a new class of technetium complexes: The hexakis(alkylisonitrile)-technetium (I) cations
70. Myocardial uptake and retention of Tc-99m-hexakis-aliphatic isotnitriles: Evidence for specificity
71. Cationic radiotracers as myocardial radiopharmaceuticals: Progress and clinical perspectives
72. Single photon radiopharmaceuticals for imaging myocardial perfusion
73. Coordination compounds in nuclear medicine
74. 99mTc-radiopharmaceuticals
75. 99mTc radiopharmaceuticals
76. Bis(dithiocarbamato)nitrido technetium-99m radiopharmaceuticals: A class of neutral myocardial imaging agents
77. Technetium-99m complexes of functionalised diphosphines for myocardial imaging
78. 99mTc myocardial perfusion imaging agents
79. Novel functionalised diphosphine complexes of Tc-99m for myocardial imaging in man
80. Technetium-99m-1,2-bis-(bis[2-ethoxyethyl]phosphino)ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent
81. Phase I study of Tc-99m diphosphine (P53) for myocardial imaging
82. 99mTc complexes
83. New oxotechnetium (V) complexes of N,N′-ethylene bis(acetylacetone imine), N,N′-ethylene(salicylideneamine), and O'phenylenebis(salicylidene amine). X-ray structures of the complexes of N, N′-ethylene bis(acetylacetone imine) and N,N′-ethylene(salicylideneamine)
84. Human biodistribution, dosimetry and clinical use of technetium (III)-99m-Q12
85. A definition of substrate specificity in renal transport of organic anions
86. Synthesis and biological evaluation of Technetium-99m N,N′-bis(mercaptoacetyl)-2,3-diaminopropionate: A potential replacement for I-131-o-iodohippurate
87. Radio-HPLC: Application to organic and metal chelate chemistry in analytical and chromatographic techniques
88. 3 as a hippuran-replacement
89. Two-component kit with nonradioactive precursor for the preparation of an enantiomeric form of the kidney function diagnostic agent, Technetium-99m-labeled mercaptoacetyltriglycine
90. 3 and biodistribution of by-products
91. New developments in radiopharmaceuticals
92. 99mTc mercaptoacetyltripeptides in mice and a baboon
93. Tc-99m-L,L-ethylene dicysteine as a renal imaging agent. I. Labeling and evaluation in animals
94. 99mTc-ECD and their biodistribution in mice
95. 99mTc-DMDTPA
96. A potential new cationic renal tubular agent: Evaluation in normal human volunteers of Tc-99m-diaminocyclohexane (DACH)
97. The uptake mechanisms of inflammation- and infection-localizing agents
98. Radiopharmaceuticals for the study of inflammatory processes: A review
99. Survey of radioactive agents for in-vitro labeling of phagocytic leukocytes. I. Soluble agents
100. Editorial: What is the best method for imaging focal infections?
101. Radiolabeling of blood cells: Methodology
102. A method for stabilizing technetium-99m exametazime prepared from a commercial kit
103. 99mTc-ECD as a white blood cell labeling agent
104. 99mTc-amine phenol chelates
105. 99mTc complexes for functional imaging: Genesis of development and recent trends
106. Retention of Technetium-99m in infectious foci in rats after release from Technetium-99m-labeled human non-specific polyclonal immunoglobulin G: A dual-label study with hydrazinonicotinamido and iminothiolano immunoglobulin
107. Tc-99m-human polyclonal IgG radiolabelled via the hydrazino nicotinamide derivative for imaging focal sites of infection of rats
108. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals
109. 99mTc-infecton imaging with radiolabeled white cell imaging in the evaluation of bacterial infection
110. Ciprofloxacin in imaging of infective versus sterile inflammation
111. Technetium-99m-labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations
112. Radiolabelled antimicrobial peptides for imaging of infection
113. Ubiquicidin, a novel murine antimicrobial protein in the cytosolic fraction of activated macrophages
114. 99mTc-neutrophil elastase inhibitor in monkeys
115. Labeling peptides with Tc-99m using a bifunctional chelator of a N-hydroxy succinimide ester of mercaptoacetyl triglycine
116. 99mTc-labeled anti-CD15 monoclonal antibody imaging for diagnosis of equivocal appendicitis
117. Technetium-99m-labeled anti-SSEA-1 antibody for human neutrophils: In vivo evaluation and assessment as an agent for imaging infectious diseases
118. 99mTc-dimercaptosuccinate complex as a tumour imaging agent
119. 99mTc(V)-DMSA complex: Studies in medullary carcinoma of thyroid
120. Tumour imaging using Tc-99m-citrate
121. The chemical identity of pentavalent technetium-99m-dimercaptosuccinic acid
122. Radiopharmaceuticals for oncology: Status and newer trends - An overview
123. 99mTc-sestamibi in tumour imaging
124. Breast cancer detection with Tc-99m-Tetrofosmin
125. Technetium-99m-d,l-hexamethylpropyleneamineoxime (HMPAO) uptake and glutathione content in brain tumors
126. 99mTc-GHA in human cerebral gliomas
127. Technetium-99m labeling of DNA oligonucleotides
128. Non-invasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography
129. TcO (PnAO-1-2-nitroimidazole) [BMS181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization and xanthine oxidase-catalysed reduction
130. Imaging ischemic tissue at risk of infarction during stroke
131. 99mTechnetium-nitroimidazole complex based on a bis(amine-phenol) ligand: Comparison to BMS-181321
132. Technetium-99m HL-91: A potential new marker of myocardial viability assessed by nuclear imaging early after reperfusion
133. Nicotinamide-substituted complexes as redox markers. I. Synthesis and UV estimation of rhenium and technetium mixed-ligand systems
134. Chelating agents for the binding of metal ions to macromolecules
135. Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium
136. Synthesis, characterization and x-ray structural determination of Technetium-(V)-oxotetradentate amine-oxime complexes
137. 2 core
138. Synthesis and characterization of a series of isomeric oxotechnetium(V) diamidodithiolates
139. Synthesis and characterization of technetium and rhenium complexes of N,N′-1,2-ethylenediylbis-L-cysteine. Neurolite and its metabolites
140. 3OMe)
141. 5OH
142. Synthesis and characterization of neutral oxotechnetium (V) bis aminoethane thiol complexes: Potential brain imaging agents
143. 2N′S peptidic chelator: Evidence of interconversion between the syn and anti conformations
144. 4 for use in labeling proteins with metallic radionuclides
145. Preparation and x-ray structure of trans-dioxo(1,4,8,11-tetraazacyclotetradecane) technetium(V) perchlorate hydrate
146. 2
147. 99mTc-labelled conjugated antibodies using a cyclam-based bifunctional chelating agent
148. Radiolabelled somatostatin analogs in prostate cancer
149. μ-oxo-bis-oxo complexes of Tc(V) with amine phenol ligands: Synthesis, characterization and x-ray crystal structures
150. Synthesis and characterization of Technetium (V) Oxo-complexes with quadridentate Schiff-base ligands: X-ray structures of μ-oxo-bis-{oxo[N,N′-propane-1,3-diyl-bis(salicylideneiminato)] technetium(V)} and chloro-oxo[N,N′-propane-1,3-diylbis(salicylideneiminato)] technetium(V)
151. Low-symmetry, mixed-valent, μ-Oxo technetium complexes with pyridine and halide ligands
152. Dinuclear complexes of Re(V) with amine-phenol ligands. Syntheses, characterization and x-ray crystal structures
153. Studies of Tc complexes 9. Use of tetrachloronitridotechnetate (VI) anion for the preparation of nitrido complexes of technetium. Crystal structure of bis(8-quinolinethiolato)nitridotechnetium(V)
154. Development of new technetium cores containing technetium-nitrogen multiple bonds. Synthesis and characterization of some diazenido-hydrazido- and imido-complexes of technetium
155. Formation of the Tc≡N multiple bond from the reaction of ammonium pertechnetate with S-methyl dithiocarbazate and its application to the preparation of technetium-99m-radiopharmaceuticals
156. 2] (noet= N-ethyl-N-ethoxydithiocarbamato)
157. Technetium-99m dithiocarbamates as potential brain agents: Evaluation of aliphatic and amine containing analogues
158. 9)(X=Cl, Br; dioxime = Dimethylglyoxime, cyclohexanedione dioxime)
159. 99mTc complexes
160. 99mTc-complexes of polydentate tris-amineoximes
161. Technetium-99m-tetrofosmine as a new radiopharmaceutical for myocardial perfusion imaging
162. Design and development of functionalized water-soluble phosphines: Catalytic and biomedical implications
163. 99mTc complexes
164. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine based-bifunctional chelating agent
165. A novel ternary ligand system for Tc-99m labeling of hydrazinonicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands
166. Potential technetium small molecule radiopharmaceuticals
167. - (where M= Re, Tc) or-ganodiazenido, organodiazene-chelate complexes
168. yNNR)} core and their relationship to radiolabeled organohydrazine-derivatized chemotactic peptides with diagnostic applications
169. The synthesis and characterisation of technetium and rhenium hydrazinopyrimidine chelate complexes
170. New and versatile ternary ligand system for technetium radiopharmaceuticals: Water soluble phosphines and tricene as coligand labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with Tc-99m
171. Synthesis, evaluation and Tc-99m complexation of a hydrazinonicotinyl conjugate of a GP IIb/IIIa antagonistic cyclic peptide for the detection of deep-vein thrombosis
172. 3-HSA as possible blood pool agents
173. 3 chelate for radioimmunotherapy of cancer. A technical protocol
174. 186Re-labeling of monoclonal antibodies
175. Technetium-99m chelate-containing receptor-binding peptides
176. Somatostatin receptor-binding peptides labeled with technetium-99m: Chemistry and initial biological studies
177. Thrombus imaging using Technetium-99m-labeled high-potency GP IIb/IIIa receptor antagonist. Chemistry and initial biological studies
178. 99mTc-labeling kinetics of four thiol-containing chelators and 2-hydrazinopyridine: Factor influencing their radiolabeling efficiency
179. Bifunctional chelators for Technetium-99m
180. 99mTc complexes
181. Stability versus reactivity of "3 + 1" mixed-ligands Technetium-99m complexes in vitro and in vivo
182. 6]
183. Application of technetium and rhenium carbonyl chemistry to nuclear medicine
184. +"(M= Re, Tc) fragment for the labeling of proteins and small molecules
185. + moieties and macrocyclic thioethers of various ring sizes: Synthesis and x-ray structure of the complexes
186. 3CN)}(M= Tc, Re)
187. 3]
188. 2: Novel technetium complex of 1,4,7-triazacyclononane and hydriditris(pyrazolyl) borate
189. 12]
190. Synthesis of rhenium(I) and technetium(I) carbonyl/dithioether ligand complexes bearing 3,17β-estradiol
191. Tc-99m-Markierung von cymantren-analogen verbindugen mit verschiedenen substituenten-Ein neuer zugang zu Tc-99m radiodiagnostika
192. 99mTc-markierten cytectren-carbonsaure mit alkoholen cyclischer amine als gehirn-affine radiodiagnostica
193. Rhenium carbonyl complexes of β-estradiol derivatives with high affinity for estradiol receptors: An approach to selective organometallic radiopharmaceuticals
194. Synthesis of a tetradentate oxorhenium (V) complex mimic of a steroidal estrogen
195. Preparation of cyclopentadienyltricarbonylrhenium complexes using a double ligand transfer reaction
196. A convenient three-component synthesis of substituted cyclopentadienyl tricarbonyl rhenium complexes
197. A convenient three-component synthesis of substituted cyclopentadienyl tricarbonyl Re(I) and Tc(I) complexes and its potential for radiolabeling
198. Protein and peptide labeling with (cyclopentadienyl)tricarbonyl rhenium and technetium
199. Synthesis and biological evaluation of Tc-99m-cyclopentadienyltricarbonyltechnetium-labeled octreotide
200. A ticket to ride: Peptide radiopharmaceuticals
201. "Magic bullets": From muskets to smart bombs
202. From monoclonal antibodies to peptides and molecular recognition units: An overview
203. Peptide radiopharmaceuticals in nuclear medicine
204. Recent developments in the radiolabeling of antibodies with iodine, indium and technetium
205. Antibody radiolabeling, problems and promises
206. A novel approach to Tc-99m-labeled monoclonal antibodies
207. Reduction mediated technetium-99m labeling of monoclonal antibodies
208. Technetium-99m-labeled monoclonal antibodies: Evaluation of reducing agents
209. Technetium-99m labeling of murine monoclonal antibody fragments
210. 99mTc-labelled monoclonal antibody fragments
211. New facile methods of stably labeling antibodies with technetium-99m
212. A rapid and efficient method of labeling IgG antibodies with Tc-99m and comparison to Tc-99m Fab' antibody fragments
213. 99mTc-labeled biotin conjugate in a tumor "pretargeting" approach with monoclonal antibodies
214. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ-219-387) labeled with Technetium-99m
215. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: Recent developments and encouraging results
216. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer
217. Progestin rhenium complexes: Metal-labeled steroids with high receptor-binding affinity, potential receptor directed agents for diagnostic-imaging or therapy
218. 2-metal conjugate
219. Selective formation of heterodimeric bis-bidentate aminethiol-oxometal complexes of Rhenium (V)
220. Homodimeric and heterodimeric bis(aminethiol) oxometal complexes with Rhenium(V) and Technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones
221. Synthesis of oxorhenium (V) complexes derived from 7-alpha-functionalized testosterone derivatives
222. Synthesis of "3 + 1" mixed-ligand oxorhenium (V) complexes containing modified 3,17β-estradiol
223. Relationship between lipophilicity and brain extraction of C-11-labelled radiopharmaceuticals
224. 99mTc]TRODAT-1: A novel technetium-99m complex as a dopamine transporter imaging agent
225. Synthesis and characterisation of Tc-99m-labeled tropanes as dopamine transporter imaging agents
226. 99mTc]TRODAT-1 as dopamine transporter imaging agents
227. Technepine: A high-affinity Tc-99m probe to label the dopamine transporter in brain by SPECT imaging
228. Novel rhenium complexes derived from α-Tropanol as potential ligands for the dopamine transporter
229. TROTEC-1: A new high-affinity ligand for labeling of the dopamine transporter
230. Structural modification of receptor-binding technetium-99m complexes in order to improve brain uptake
231. 2A serotonin receptor binding: Structure-affinity considerations
232. Therapeutic approaches related to amyloid-β peptide and Alzheimer's disease
233. Technetium complexes for the quantitation of brain amyloid